Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06873724
PHASE1

A Study of SPY003-207 in Healthy Volunteers

Sponsor: Spyre Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY003-207 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

59

Start Date

2025-03-10

Completion Date

2026-11-18

Last Updated

2026-03-20

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

SPY003-207

Experimental

OTHER

Placebo

Placebo

Locations (2)

Spyre Site 2

Cypress, California, United States

Spyre Site 1

Montreal, Quebec, Canada